Država: Nova Zelandija
Jezik: angleščina
Source: Medsafe (Medicines Safety Authority)
Emtricitabine 200mg; ; ; ; ; Tenofovir alafenamide fumarate 11.2mg equivalent to 10 mg Tenofovir alafenamide;
Gilead Sciences (NZ)
Emtricitabine 200 mg
200mg/10mg
Film coated tablet
Active: Emtricitabine 200mg Tenofovir alafenamide fumarate 11.2mg equivalent to 10 mg Tenofovir alafenamide Excipient: Croscarmellose sodium Magnesium stearate Microcrystalline cellulose Opadry grey 85F97517
Prescription
Union Quimico Farmaceutica SA (Uquifa SA)
DESCOVY is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and adolescents aged 12 years and older with body weight at least 35 kg. The patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of DESCOVY. DESCOVY is not for use in Pre-Exposure Prophylaxis (PrEP)?.
Package - Contents - Shelf Life: Bottle, plastic, 60 mL HDPE white bottle with PP CRC cap lined with an induction activated al foil liner - 30 tablets - 36 months from date of manufacture stored at or below 30°C
2016-07-13
DESCOVY® 1 DESCOVY® CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side effects. See the full CMI for further details. 1. WHY AM I USING DESCOVY? DESCOVY contains the active ingredients emtricitabine and tenofovir alafenamide. DESCOVY is used to: • treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults and children aged 12 years of age and older and weighing ≥ 35 kg when taken in combination with other anti-HIV medicines For more information, see Section 1. Why am I using DESCOVY? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE DESCOVY? Do not use if you have ever had an allergic reaction to DESCOVY or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use DESCOVY? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with DESCOVY and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE DESCOVY? • The usual dose is one DESCOVY tablet orally, once daily. • Take DESCOVY with or without food. More instructions can be found in Section 4. How do I use DESCOVY? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING DESCOVY? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using DESCOVY. THINGS YOU SHOULD NOT DO • Do not stop using this medicine suddenly. • Do not breastfeed. • Avoid doing things that can spread HIV infection. DRIVING OR USING MACHINES • Be careful driving or operating machinery until you know how DESCOVY affects you. LOOKING AFTER YOUR MEDICINE • Keep your DESCOVY tablets in the bottle with the cap tightly closed until yo Preberite celoten dokument
DESCOVY Data Sheet v6.0 – (15 March 2022) Page 1 NEW ZEALAND DATA SHEET 1 DESCOVY® (EMTRICITABINE/TENOFOVIR ALAFENAMIDE) TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Emtricitabine (FTC) 200 mg/Tenofovir Alafenamide (TAF) 25 mg, Emtricitabine 200 mg/Tenofovir Alafenamide 10 mg. For full list of excipients, see section 6.1 List of Excipients. 3 PHARMACEUTICAL FORM Film-coated tablet. Each 200/25 mg DESCOVY tablet is rectangular shaped, film-coated and blue in colour. Each tablet is debossed with “GSI” on one side and the number “225” on the other side. Each 200/10 mg DESCOVY tablet is rectangular shaped, film-coated and gray in colour. Each tablet is debossed with “GSI” on one side and the number “210” on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS DESCOVY is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents aged 12 years and older with body weight at least 35 kg. The patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of DESCOVY (see section 5.2 Pharmacokinetic Properties). DESCOVY is not for use in Pre ‐ Exposure Prophylaxis (PrEP). 4.2 DOSE AND METHOD OF ADMINISTRATION In adults and adolescent patients aged 12 years and older and weighing ≥ 35 kg DESCOVY is taken orally once daily with or without food. The recommended dose of DESCOVY is 200/25 mg. If DESCOVY is used in combination with an HIV-1 protease inhibitor (PI) that is administered with either ritonavir or cobicistat (COBI), the recommended dose of DESCOVY is 200/10 mg (see Table 1). DESCOVY Data Sheet v6.0 – (15 March 2022) Page 2 TABLE 1. DOSE OF DESCOVY ACCORDING TO THIRD AGENT IN THE HIV TREATMENT REGIMEN DOSE OF DESCOVY THIRD AGENT IN HIV TREATMENT REGIMEN a DESCOVY 200/10 mg once daily Atazanavir with ritonavir or cobicistat Darunavir with ritonavir or cobicistat b Lopinavir with ritonavir DESCOVY 200/25 mg once daily Do Preberite celoten dokument